Equities

Pacira Biosciences Inc

Pacira Biosciences Inc

Actions
  • Price (EUR)15.90
  • Today's Change-0.50 / -3.05%
  • Shares traded0.00
  • 1 Year change-40.23%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments279289656
Total Receivables, Net1069896
Total Inventory1049699
Prepaid expenses221515
Other current assets, total------
Total current assets510498866
Property, plant & equipment, net235254265
Goodwill, net163163145
Intangibles, net483541624
Long term investments386422
Note receivable - long term------
Other long term assets------
Total assets1,5741,6812,075
LIABILITIES
Accounts payable161511
Accrued expenses6592126
Notes payable/short-term debt000
Current portion long-term debt/capital leases8.6434375
Other current liabilities, total8.537.309.38
Total current liabilities97148521
Total long term debt514656675
Total debt5226891,049
Deferred income tax------
Minority interest------
Other liabilities, total93103149
Total liabilities7049061,345
SHAREHOLDERS EQUITY
Common stock0.050.050.05
Additional paid-in capital977924942
Retained earnings (accumulated deficit)(107)(149)(212)
Treasury stock - common------
Unrealized gain (loss)0.12(0.52)0.14
Other equity, total0.120.140.03
Total equity870775730
Total liabilities & shareholders' equity1,5741,6812,075
Total common shares outstanding464645
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.